Palvella Therapeutics (PVLA) Total Current Liabilities (2013 - 2026)
Palvella Therapeutics (PVLA) reported Total Current Liabilities of $9.1 million for Q1 2026, up 1.47% year-over-year from $9.0 million in Q1 2025, and down 19.65% on a QoQ basis from $11.3 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Total Current Liabilities data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Total Current Liabilities rose 1.47% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 1.47% YoY) and the FY2025 annual result came in at $11.3 million, down 5.77% from the prior year.
- Total Current Liabilities retreated to $9.1 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $42.9 million in Q1 2023 and bottomed at $2.4 million in Q4 2023.
- The 5-year median for Total Current Liabilities is $11.3 million (2025), against an average of $19.6 million.
- The widest annual swing landed in 2023, when Total Current Liabilities slumped 93.55%; it then jumped 410.08% in 2024.
- Tracing PVLA's Total Current Liabilities over 5 years: stood at $36.6 million in 2022, then tumbled by 93.55% to $2.4 million in 2023, then jumped by 410.08% to $12.0 million in 2024, then retreated by 5.77% to $11.3 million in 2025, then decreased by 19.65% to $9.1 million in 2026.
- Per Business Quant, the three latest PVLA Total Current Liabilities figures stand at $9.1 million (Q1 2026), $11.3 million (Q4 2025), and $10.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 9.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.12 Mn |
| Dec 31, 2025 | 11.34 Mn |
| Sep 30, 2025 | 10.31 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Mar 31, 2025 | 8.98 Mn |
| Dec 31, 2024 | 12.04 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 6.35 Mn |
| Mar 31, 2024 | 7.53 Mn |
| Dec 31, 2023 | 2.36 Mn |
| Sep 30, 2023 | 28.87 Mn |
| Jun 30, 2023 | 34.37 Mn |
| Mar 31, 2023 | 42.88 Mn |
| Dec 31, 2022 | 36.58 Mn |
| Sep 30, 2022 | 33.52 Mn |
| Jun 30, 2022 | 35.55 Mn |
| Mar 31, 2022 | 39.48 Mn |
| Dec 31, 2021 | 50.56 Mn |
| Sep 30, 2021 | 49.70 Mn |
| Jun 30, 2021 | 43.93 Mn |
| Mar 31, 2021 | 30.27 Mn |
| Dec 31, 2020 | 22.15 Mn |
| Sep 30, 2020 | 19.69 Mn |
| Jun 30, 2020 | 18.26 Mn |
| Mar 31, 2020 | 20.48 Mn |
| Dec 31, 2019 | 27.00 Mn |
| Sep 30, 2019 | 39.85 Mn |
| Jun 30, 2019 | 40.93 Mn |
| Mar 31, 2019 | 41.13 Mn |
| Dec 31, 2018 | 48.08 Mn |
| Sep 30, 2018 | 40.59 Mn |
| Jun 30, 2018 | 52.33 Mn |
| Mar 31, 2018 | 54.76 Mn |
| Dec 31, 2017 | 45.78 Mn |
| Sep 30, 2017 | 39.04 Mn |
| Jun 30, 2017 | 35.80 Mn |
| Mar 31, 2017 | 11.44 Mn |
| Dec 31, 2016 | 8.38 Mn |
| Sep 30, 2016 | 9.95 Mn |
| Jun 30, 2016 | 6.42 Mn |
| Mar 31, 2016 | 6.50 Mn |
| Dec 31, 2015 | 2.80 Mn |
| Sep 30, 2015 | 2.24 Mn |
| Jun 30, 2015 | 3.02 Mn |
| Mar 31, 2015 | 2.25 Mn |
| Dec 31, 2014 | 3.52 Mn |
| Sep 30, 2014 | 4,124.00 |
| Jun 30, 2014 | 1,124.00 |
| Dec 31, 2013 | 1.77 Mn |